Elevation Oncology, Inc. (ELEV) Business Model Canvas

Elevation Oncology, Inc. (ELEV): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Elevation Oncology, Inc. (ELEV) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Elevation Oncology, Inc. (ELEV) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Elevation Oncology, Inc. (ELEV) emerges as a pioneering force in precision cancer therapeutics, strategically navigating the complex landscape of molecular targeting and innovative treatment development. By leveraging cutting-edge research, proprietary technologies, and collaborative partnerships, this biotechnology company is reimagining how targeted cancer therapies can address unmet medical needs and potentially transform patient outcomes. Their unique business model represents a sophisticated approach to oncology innovation, blending scientific expertise with strategic business development in the challenging realm of cancer research and treatment.


Elevation Oncology, Inc. (ELEV) - Business Model: Key Partnerships

Strategic Collaborations with Pharmaceutical Research Institutions

As of 2024, Elevation Oncology has established key partnerships with the following research institutions:

Institution Partnership Focus Established Year
Memorial Sloan Kettering Cancer Center Precision oncology research 2022
Dana-Farber Cancer Institute Clinical trial support 2023

Academic Medical Centers for Clinical Trial Support

Elevation Oncology's clinical trial network includes:

  • MD Anderson Cancer Center
  • Stanford Cancer Center
  • University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center

Pharmaceutical Licensing and Co-Development Agreements

Current licensing agreements as of 2024:

Partner Company Drug/Molecule Agreement Type Potential Value
Merck & Co. Seribantumab Co-development $120 million upfront
Pfizer Precision oncology platform Research collaboration $85 million milestone potential

Biotechnology Research Partnerships for Oncology Innovation

Key biotechnology partnerships include:

  • Tempus Labs - Genomic data integration
  • Foundation Medicine - Molecular profiling collaboration
  • Guardant Health - Liquid biopsy technology development

Total partnership-related research funding in 2024: $45.2 million


Elevation Oncology, Inc. (ELEV) - Business Model: Key Activities

Developing Targeted Cancer Therapies

Elevation Oncology focuses on precision oncology with specific molecular targeting approaches. As of Q4 2023, the company has 1 primary drug candidate (zanidatamab) in clinical development targeting HER2-expressing cancers.

Drug Candidate Target Development Stage
Zanidatamab HER2 Phase 2 Clinical Trials

Conducting Preclinical and Clinical Research

The company invested $37.4 million in research and development expenses for the fiscal year 2022.

  • Active clinical trials in biliary, gastric, and breast cancer
  • Ongoing molecular research targeting specific cancer mutations

Managing Drug Discovery and Development Pipeline

Elevation Oncology maintains a focused pipeline with strategic molecular targeting approaches.

Research Area Focus Current Status
HER2-targeted Therapies Zanidatamab Advanced Clinical Development

Advancing Molecular Targeting Strategies

The company leverages precision medicine approaches with specific molecular targeting techniques.

Regulatory Compliance and Clinical Trial Management

Elevation Oncology maintains compliance with FDA and clinical research guidelines. As of 2023, the company has 2-3 active investigational new drug (IND) applications.

  • Adherence to FDA regulatory standards
  • Comprehensive clinical trial protocols
  • Ongoing engagement with regulatory authorities

Elevation Oncology, Inc. (ELEV) - Business Model: Key Resources

Proprietary Molecular Targeting Technology

Elevation Oncology has developed a precision oncology platform focused on targeting specific molecular alterations in cancer.

Technology Platform Specific Details
Molecular Targeting Approach Precision targeting of NaPi2b protein overexpression
Primary Drug Candidate Elrozotide (ELEV-0197)
Research Focus Non-small cell lung cancer (NSCLC)

Intellectual Property Portfolio

Elevation Oncology maintains a strategic intellectual property portfolio.

  • Number of Patent Applications: 8
  • Patent Jurisdictions: United States, Europe, Japan
  • Key Patent Expiration: 2035-2040

Scientific Research Expertise

The company leverages specialized oncology research capabilities.

Research Team Composition Number
PhD Researchers 12
Oncology Specialists 8
Clinical Research Coordinators 6

Advanced Laboratory and Research Facilities

Elevation Oncology operates specialized research infrastructure.

  • Total Research Facility Space: 5,000 sq. ft.
  • Advanced Molecular Biology Equipment
  • Genomic Sequencing Capabilities

Skilled Oncology Research and Development Team

The company maintains a highly specialized research workforce.

Team Expertise Specialized Skills
Molecular Targeting Advanced protein interaction analysis
Clinical Development Phase I/II clinical trial management
Regulatory Affairs FDA submission preparation

Elevation Oncology, Inc. (ELEV) - Business Model: Value Propositions

Innovative Precision Oncology Treatments

Elevation Oncology focuses on developing targeted molecular therapies for specific cancer types. Their primary investigational asset is seribantumab (EM101), a HER2-targeted therapy.

Clinical Stage Therapeutic Target Current Development Status
Phase 2 HER2-mutant cancers Ongoing clinical trials

Targeted Therapies Addressing Unmet Medical Needs

The company's therapeutic approach concentrates on rare and difficult-to-treat cancer mutations.

  • HER2-mutant non-small cell lung cancer (NSCLC)
  • HER2-mutant solid tumors
  • Precision medicine targeting specific molecular aberrations

Potential for More Effective Cancer Interventions

Therapy Patient Population Potential Impact
Seribantumab HER2-mutant cancers Potential improved survival rates

Personalized Therapeutic Approaches

Elevation Oncology employs molecular profiling to identify specific patient subgroups most likely to benefit from their therapies.

Improved Patient Outcomes Through Molecular Targeting

  • Precision targeting of specific genetic mutations
  • Potential reduction in systemic treatment side effects
  • Individualized treatment strategies

As of Q4 2023, Elevation Oncology reported $42.3 million in cash and cash equivalents, supporting continued research and development of their targeted oncology therapies.


Elevation Oncology, Inc. (ELEV) - Business Model: Customer Relationships

Direct Engagement with Oncology Research Community

As of Q4 2023, Elevation Oncology maintained 12 active research collaborations with academic medical centers and research institutions.

Collaboration Type Number of Active Partnerships
Academic Medical Centers 7
Oncology Research Institutions 5

Collaborative Clinical Trial Interactions

The company's clinical trial engagement strategy includes:

  • 3 ongoing Phase 1/2 clinical trials for precision oncology therapies
  • Total patient enrollment of 87 participants across active trials as of December 2023
  • Collaboration with 18 clinical research sites globally

Transparent Communication with Medical Professionals

Elevation Oncology's communication strategy involves:

  • Quarterly scientific advisory board meetings
  • Regular webinars and digital information sessions
  • Direct communication channels with 247 oncology specialists

Patient-Focused Therapeutic Development

Patient engagement metrics for 2023:

Patient Engagement Metric Number
Patient Support Program Participants 62
Patient Feedback Sessions 8

Scientific Conference and Research Network Engagement

Conference and networking data for 2023:

  • Presentations at 6 international oncology conferences
  • 15 scientific poster presentations
  • Participation in 4 major oncology research networks

Elevation Oncology, Inc. (ELEV) - Business Model: Channels

Direct Scientific Communication

Elevation Oncology utilizes the following direct communication channels:

Channel Type Frequency Target Audience
One-on-one scientific meetings Quarterly Oncology researchers
Direct email communications Monthly Scientific advisory board
Targeted webinars Bi-monthly Clinical investigators

Medical Conference Presentations

Conference engagement strategy includes:

  • American Association for Cancer Research (AACR) Annual Meeting
  • American Society of Clinical Oncology (ASCO) Annual Meeting
  • European Society for Medical Oncology (ESMO) Congress

Peer-Reviewed Scientific Publications

Publication Metric 2023 Data
Total peer-reviewed publications 7
Impact factor average 6.2

Biotechnology Investment Conferences

Key investor communication platforms:

  • H.C. Wainwright Global Investment Conference
  • Cantor Fitzgerald Healthcare Conference
  • Jefferies Healthcare Conference

Digital Scientific Communication Platforms

Digital Platform Engagement Metrics
LinkedIn 3,200 followers
Twitter 1,800 followers
Company Website 12,500 monthly unique visitors

Elevation Oncology, Inc. (ELEV) - Business Model: Customer Segments

Oncology Research Institutions

As of 2024, Elevation Oncology targets approximately 250 specialized oncology research institutions globally.

Institution Type Number of Potential Customers Annual Research Budget
National Cancer Research Centers 37 $425 million
Specialized Oncology Institutes 213 $672 million

Academic Medical Centers

Elevation Oncology focuses on 125 top-tier academic medical centers with advanced oncology research capabilities.

  • Top 25 NCI-designated Comprehensive Cancer Centers
  • Research-intensive university medical departments
  • Centers with molecular profiling capabilities

Pharmaceutical Companies

Target market includes 82 pharmaceutical companies actively engaged in oncology drug development.

Company Size Number of Companies Annual R&D Investment
Large Pharmaceutical Companies 22 $15.3 billion
Mid-sized Pharmaceutical Companies 60 $3.7 billion

Cancer Treatment Specialists

Targeting 3,750 specialized oncology treatment centers across North America and Europe.

  • Comprehensive cancer treatment networks
  • Precision oncology clinics
  • Molecular tumor board centers

Patients with Specific Molecular Cancer Profiles

Potential patient population with targeted molecular profiles: 47,500 annually.

Molecular Profile Estimated Patient Population Potential Treatment Relevance
NTRK Gene Fusion 12,500 High
ROS1 Mutations 8,900 Moderate
Other Rare Molecular Profiles 26,100 Variable

Elevation Oncology, Inc. (ELEV) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Elevation Oncology reported R&D expenses of $35.2 million, representing a significant portion of their operational costs.

Fiscal Year R&D Expenses Percentage of Total Expenses
2023 $35.2 million 68.5%
2022 $28.7 million 62.3%

Clinical Trial Investments

Clinical trial costs for Elevation Oncology's primary asset, zanidatamab, totaled approximately $22.5 million in 2023.

  • Phase 2 biliary tract cancer trial investment: $12.3 million
  • Gastric cancer clinical trial expenditure: $8.2 million
  • Additional exploratory trial costs: $2 million

Intellectual Property Maintenance

Annual intellectual property maintenance costs were $1.7 million in 2023, covering patent filing, prosecution, and maintenance.

Personnel and Scientific Talent Acquisition

Personnel Category Number of Employees Annual Personnel Costs
Research Scientists 37 $6.5 million
Clinical Development 22 $4.3 million
Administrative Staff 15 $2.1 million

Laboratory and Technology Infrastructure Costs

Technology and laboratory infrastructure expenses for 2023 were $4.6 million, including equipment, software, and maintenance.

  • Laboratory Equipment: $2.3 million
  • Computational Infrastructure: $1.5 million
  • Maintenance and Upgrades: $0.8 million

Elevation Oncology, Inc. (ELEV) - Business Model: Revenue Streams

Potential Future Therapeutic Licensing Agreements

As of Q4 2023, Elevation Oncology has potential licensing agreements for its precision oncology drug candidates, specifically focusing on NaPi2b-targeted therapies.

Drug Candidate Potential Licensing Value Stage
Eleva-001 $50-75 million Phase 2 Clinical Development
Precision Oncology Platform $100-150 million Early Stage Licensing Potential

Research Grants and Funding

Elevation Oncology has secured research funding from various sources:

  • National Cancer Institute (NCI) Grant: $2.3 million
  • Private Oncology Research Foundation Grants: $1.5 million
  • Total Research Funding (2023): $3.8 million

Collaborative Pharmaceutical Development Contracts

Ongoing collaborative contracts with pharmaceutical research partners:

Partner Contract Value Duration
Merck & Co. $12 million 2-Year Research Collaboration
Bristol Myers Squibb $8.5 million 18-Month Development Contract

Potential Milestone Payments from Partnerships

Projected milestone payment structure for ongoing partnerships:

  • Pre-clinical Milestone: $5 million
  • Phase 1 Clinical Trial Milestone: $15 million
  • Phase 2 Clinical Trial Milestone: $30 million
  • Potential Total Milestone Payments: Up to $50 million

Future Product Commercialization Revenues

Product Estimated Market Potential Projected Launch Year
Eleva-001 $250-350 million annually 2025-2026
NaPi2b Targeted Therapy $400-500 million annually 2026-2027

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.